UBS published a report stating that WuXi AppTec's revenue in the third quarter increased by 15% year-on-year to 12.1 billion yuan, exceeding the bank's and market forecasts of 11.4 billion yuan and 11.5 billion yuan; net profit increased by 53% year-on-year to 3.5 billion yuan, exceeding the bank's and market forecasts of 3.3 billion yuan and 3.1 billion yuan. As of the end of the third quarter, the backlog of orders for continuing operations increased by 41% year-on-year to 59.9 billion yuan. The company also announced the divestiture of its clinical contract research organization/site management organization business, with an initial transaction price of 2.8 billion yuan. The bank believes that the sale is beneficial to WuXi AppTec as the company can focus on its core contract research, development and manufacturing organization business and its global expansion. The bank raised its earnings per share forecast for the company this year by 23.4%, and its earnings forecast for next year to 2028 by 0.3% to 0.9%; the target price was raised from HK$136.1 to HK$138.4, and the rating was "buy".